Avi Retter, MD
Hematology & Oncology · Bronx, NYNPI 1205894268
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Johnson & Johnson at 53.1% of the total. Reporting peaked in 2024 at $2,230 and has fallen 98.3% since, to $37 in 2025.
Across 97 payments — averaging $72.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Karyopharm Therapeutics Inc.$2K
- Puma Biotechnology, Inc.$147
- AstraZeneca$99
- Gilead$98
- Takeda Pharmaceuticals U.S.A., Inc.$98
- plus $992 from 28 others
What the payments were for
- Consulting fees$3,39848%
- Speaking & faculty fees$1,87527%
- Food & beverage$1,65723%
- Education$1292%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 15 | $3,749 |
| Karyopharm Therapeutics Inc. | 1 | $1,875 |
| Puma Biotechnology, Inc. | 8 | $147 |
| AstraZeneca(2 entities) | 6 | $99 |
| Gilead(2 entities) | 6 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Amgen | 4 | $85 |
| Pfizer | 4 | $71 |
| Lilly USA, LLC | 4 | $70 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Secura Bio, Inc. | 4 | $65 |
| Astellas Pharma US Inc | 3 | $60 |
| Boehringer Ingelheim | 4 | $56 |
| EMD Serono, Inc. | 2 | $50 |
| Seagen Inc. | 3 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Array Biopharma Inc | 1 | $38 |
| Merck | 2 | $32 |
| Eisai Inc. | 2 | $30 |
| Stemline Therapeutics Inc. | 2 | $30 |
| Epizyme, Inc. | 2 | $30 |
| Advanced Accelerator Applications | 1 | $24 |
| Bristol Myers Squibb | 2 | $24 |
| Dova Pharmaceuticals | 1 | $22 |
| Sanofi | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Bayer | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Myovant Sciences Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $12 |
| Incyte Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,058 in reported general payments places this provider in the 70th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 96 | $1,433,616 |
| Lupron DepotLeuprolide Acetate | 142 | $805,524 |
| RevlimidLenalidomide | 41 | $625,496 |
| ImfinziDurvalumab | 52 | $560,955 |
| PomalystPomalidomide | 24 | $539,631 |
| AranespDarbepoetin Alfa In Polysorbat | 246 | $487,173 |
| KyprolisCarfilzomib | 38 | $433,480 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 23 | $356,619 |
| IbrancePalbociclib | 22 | $348,208 |
| CabometyxCabozantinib S-Malate | 12 | $308,562 |
| CalquenceAcalabrutinib Maleate | 19 | $293,121 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 69 | $274,904 |
| ErleadaApalutamide | 17 | $254,147 |
| AlecensaAlectinib Hcl | 12 | $223,577 |
| Neulasta OnproPegfilgrastim | 34 | $205,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $60 | $1,433,61696 claims |
| AmgenAranesp, Kyprolis, Xgeva, Riabni, Mvasi | $85 | $1,320,030376 claims |
| AstraZenecaImfinzi, Calquence | $99 | $854,07671 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Opdivo | $38 | $721,98236 claims |
| PfizerIbrance, Octagam, Eliquis | $71 | $667,273150 claims |
| Bristol Myers SquibbRevlimid | $24 | $625,49641 claims |
| Johnson & JohnsonErleada, Procrit, Xarelto | $3,749 | $470,402140 claims |
| Genentech USA, Inc.Alecensa | $12 | $223,57712 claims |
| MerckKeytruda | $32 | $123,84411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $98 | $41,88622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Bronx
- Tauseef AhmedBronx$171K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.